PFE: Pfizer Inc.
About
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Current Value
$25.071 Year Return
Current Value
$25.071 Year Return
Key Details
Market Cap
$142.24B
P/E Ratio
33.74
1Y Stock Return
-17.16%
1Y Revenue Growth
-12.29%
Dividend Yield
5.73%
Price to Book
1.5
Strategies that include PFE
Stock's related to PFE
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| JNJ | 41.70% | $368.37B | +1.24% | 3.18% |
| BNTX | 41.30% | $25.51B | +9.51% | 0.00% |
| MRNA | 35.60% | $14.35B | -51.66% | 0.00% |
| TECH | 31.30% | $10.55B | +4.49% | 0.48% |
| BMY | 31.17% | $118.10B | +20.11% | 4.09% |
| ATEN | 30.88% | $1.21B | +34.32% | 1.46% |
| VOYA | 30.63% | $7.69B | +13.25% | 2.06% |
| AJG | 29.66% | $64.17B | +17.51% | 0.80% |
| VLTO | 28.88% | $25.72B | +43.80% | 0.34% |
| WTW | 28.78% | $30.98B | +26.60% | 1.13% |
| AWR | 28.74% | $3.22B | +7.55% | 2.09% |
| QGEN | 28.31% | $9.05B | -1.92% | 0.00% |
| T | 28.09% | $163.09B | +40.40% | 4.87% |
| AMCR | 28.06% | $14.29B | +7.03% | 4.94% |
| WT | 28.01% | $1.69B | +80.19% | 1.04% |
| PRGO | 27.81% | $3.72B | -9.95% | 4.04% |
| RDN | 27.79% | $5.04B | +32.94% | 2.84% |
| TRN | 27.74% | $3.12B | +54.58% | 2.95% |
| AWK | 27.71% | $26.93B | +5.63% | 2.17% |
| BCE | 27.70% | $24.91B | -30.63% | 10.69% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PUBM | 0.02% | $739.82M | -2.82% | 0.00% |
| IMMP | 0.03% | $293.82M | +8.31% | 0.00% |
| NGT | -0.04% | $49.16B | +15.39% | 2.69% |
| BSY | 0.04% | $14.13B | -11.17% | 0.49% |
| CLX | -0.06% | $20.81B | +20.66% | 2.88% |
| YPF | 0.06% | $13.98B | +139.72% | 0.00% |
| BASE | -0.07% | $1.04B | +8.03% | 0.00% |
| VICR | 0.09% | $2.40B | +39.81% | 0.00% |
| LU | 0.09% | $2.01B | -33.75% | 0.00% |
| TPST | -0.11% | $37.75M | -77.59% | 0.00% |
| TGLS | -0.13% | $3.54B | +120.49% | 0.56% |
| UCTT | 0.16% | $1.60B | +35.62% | 0.00% |
| META | 0.17% | $1.42T | +66.51% | 0.27% |
| LUMO | -0.18% | $37.45M | +41.97% | 0.00% |
| PGY | 0.19% | $634.91M | -45.99% | 0.00% |
| TECK | 0.19% | $24.49B | +31.13% | 0.78% |
| CRWD | 0.19% | $86.61B | +69.05% | 0.00% |
| VET | 0.19% | $1.57B | -21.53% | 3.35% |
| ICHR | -0.20% | $1.03B | +18.32% | 0.00% |
| SPOT | 0.20% | $90.80B | +159.59% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| STTK | -15.54% | $54.42M | -50.22% | 0.00% |
| AVGO | -14.03% | $772.28B | +68.52% | 9.87% |
| AAOI | -13.98% | $1.29B | +114.18% | 0.00% |
| NVDA | -12.93% | $3.61T | +194.35% | 0.07% |
| HMST | -12.43% | $215.54M | +82.88% | 0.00% |
| ELF | -11.78% | $6.86B | +8.95% | 0.00% |
| ANF | -11.67% | $7.28B | +92.60% | 0.00% |
| VZIO | -11.62% | $2.29B | +67.76% | 0.00% |
| FRPT | -11.60% | $7.59B | +126.44% | 0.00% |
| NFLX | -11.40% | $372.45B | +83.46% | 0.00% |
| CAMT | -11.25% | $3.40B | +16.39% | 0.00% |
| HUBS | -11.08% | $35.23B | +44.73% | 0.00% |
| CMG | -11.04% | $80.02B | +33.62% | 0.00% |
| NTNX | -10.90% | $18.33B | +70.72% | 0.00% |
| PBPB | -10.83% | $293.68M | +4.36% | 0.00% |
| NVMI | -10.72% | $5.16B | +44.02% | 0.00% |
| SAVA | -10.58% | $1.35B | +25.50% | 0.00% |
| ESTC | -10.53% | $9.07B | +13.94% | 0.00% |
| MOGO | -10.44% | $36.95M | +26.89% | 0.00% |
| ONTO | -10.38% | $8.04B | +20.50% | 0.00% |
ETF's related to PFE
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FDL | 39.78% | $4.50B | 0.45% |
| IHE | 37.89% | $596.23M | 0.39% |
| BBH | 37.63% | $397.87M | 0.35% |
| PPH | 37.22% | $592.06M | 0.36% |
| VHT | 36.50% | $17.06B | 0.1% |
| XLV | 36.50% | $38.41B | 0.09% |
| FHLC | 36.29% | $2.73B | 0.084% |
| IYH | 35.95% | $3.19B | 0.39% |
| IXJ | 34.93% | $3.89B | 0.41% |
| IBB | 34.69% | $6.66B | 0.45% |
| SCHD | 33.26% | $65.70B | 0.06% |
| SPHD | 33.09% | $3.46B | 0.3% |
| FBT | 33.09% | $1.11B | 0.56% |
| LVHD | 31.60% | $560.70M | 0.27% |
| HDV | 31.56% | $11.19B | 0.08% |
| RSPH | 31.47% | $885.96M | 0.4% |
| FXH | 31.39% | $1.15B | 0.62% |
| CDC | 31.32% | $821.08M | 0.38% |
| IYF | 31.05% | $3.70B | 0.39% |
| IAK | 31.04% | $760.79M | 0.39% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| STIP | 0.01% | $8.74B | 0.03% |
| IVW | 0.03% | $54.47B | 0.18% |
| BTAL | -0.03% | $388.04M | 1.43% |
| FBCG | -0.03% | $2.55B | 0.59% |
| ICLO | -0.07% | $209.30M | 0.2% |
| KMLM | 0.07% | $353.87M | 0.9% |
| TBLL | 0.09% | $1.92B | 0.08% |
| QTEC | 0.13% | $3.85B | 0.57% |
| JPST | -0.15% | $28.43B | 0.18% |
| IVOL | 0.16% | $548.70M | 1.02% |
| VGT | 0.19% | $80.62B | 0.1% |
| SPYG | 0.21% | $32.21B | 0.04% |
| IGM | -0.24% | $5.60B | 0.41% |
| AGZD | 0.25% | $142.76M | 0.23% |
| IWY | 0.26% | $12.45B | 0.2% |
| BSCQ | -0.33% | $4.02B | 0.1% |
| TCHP | 0.35% | $890.14M | 0.57% |
| FTEC | -0.42% | $12.59B | 0.084% |
| URA | -0.42% | $3.55B | 0.69% |
| DUSB | -0.42% | $797.63M | 0.15% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| TPMN | -14.44% | $40.60M | 0.65% |
| DBE | -12.39% | $50.13M | 0.77% |
| USDU | -12.07% | $201.97M | 0.5% |
| BSJO | -11.80% | $467.93M | 0.43% |
| VCAR | -11.62% | $9.00M | 1.2% |
| VIXY | -11.53% | $195.31M | 0.85% |
| GSG | -11.39% | $914.42M | 0.75% |
| COMT | -11.32% | $829.06M | 0.48% |
| DBO | -11.06% | $217.57M | 0.77% |
| DBA | -10.71% | $755.88M | 0.93% |
| CMDY | -10.67% | $279.14M | 0.28% |
| UUP | -10.61% | $309.25M | 0.77% |
| DBC | -10.59% | $1.39B | 0.87% |
| PDBC | -10.51% | $4.40B | 0.59% |
| USCI | -10.12% | $185.47M | 1.07% |
| BSCP | -9.91% | $4.05B | 0.1% |
| KCCA | -9.65% | $220.51M | 0.87% |
| EQLS | -9.63% | $76.08M | 1% |
| GCC | -9.49% | $133.23M | 0.55% |
| FTGC | -9.41% | $2.17B | 1.02% |
News
Finnhub
Firms which raised prices for key epilepsy medicine - causing NHS costs to soar to £50 million - found by the CAT to have breached competition law.* In a judgment handed down today, the CAT found...
Finnhub
Health-care companies rose as obesity-drug makers snapped back from a recent selloff. Pfizer elevated the executive in charge of its cancer-drugs business to oversee all of the drugmaker's...
MarketWatch
Pfizer Inc. stock underperforms Wednesday when compared to competitors
Yahoo
NEW YORK, November 20, 2024--Pfizer Inc. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M.D., PhD, as Chief Scientific Officer and President, Research & Development effective January 1, 2025. Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year. In his new role, Dr. Boshoff wi
Yahoo
The appointment comes at a time when Pfizer is facing criticism from activist investor Starboard for overspending on big acquisitions and failing to produce profitable new drugs from those deals or its internal research and development. The New York-based drugmaker, under CEO Albert Bourla, poured money into new deals to bolster its business, which has been struggling with a sharp fall in sales of its COVID vaccine and antiviral Paxlovid from the pandemic highs. Pfizer, which is now looking to strengthen its focus on cancer drugs, said Boshoff will take on the role of chief scientific officer starting Jan. 1 and oversee all functions of research & development across all therapeutic areas.
Yahoo
Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief scientific officer starting Jan. 1.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.